News & Perspective
Drugs & Diseases
CME & Education
Academy
Video New
Edition: ENGLISH
DEUTSCH
ESPAÑOL
FRANÇAIS
PORTUGUÊS
Sign Up It's Free!
Edition: ENGLISH DEUTSCH ESPAÑOL FRANÇAIS PORTUGUÊS
Register Log In

No Results

    News & Perspective Drugs & Diseases CME & Education Academy Video New
    Drugs & Diseases > Oncology

    Gastrointestinal Stromal Tumors Treatment Protocols 

    Updated: Feb 26, 2018
    • Author: Erin V Newton, MD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
    • Print
    Sections

    Treatment Protocols

    Treatment protocols for gastrointestinal stromal tumors (GISTs) are provided below, including those for limited-stage disease and persistent or metastatic disease.

    Limited-stage disease with possible resection

    Surgery is the primary treatment for localized or potentially resectable GISTs. Patients with a small GIST (<2 cm) may be treated with endoscopic surveillance if high-risk features are absent; high-risk endoscopic ultrasound features include the following [1, 2, 3] :

    • An irregular border
    • Cystic space
    • Ulceration
    • Echogenic foci
    • Heterogeneity

    Neoadjuvant therapy [4, 5] :

    • Neoadjuvant imatinib therapy is preferred for marginally resectable tumors or patients with comorbidities for surgery [6]
    • Neoadjuvant therapy is aimed at reducing tumor size, which may facilitate complete surgical resection.  
    • Treatment should continue until the time of maximal response, which is typically no more than 10-12 months. [7]
    • The usual dose of i matinib is 400 mg PO daily. In patients with a known exon 9 KIT mutation, a dose of 800 mg PO daily can be considered if tolerated. [8]
    • Neoadjuvant imatinib will be less effective and is therefore not recommended in cases of a platelet-derived growth factor receptor–alpha (PDGFRA) D842V mutation or a succinate dehydrogenase (SDH)–deficient or neurofibromatosis (NF)-related GIST [9, 10, 11]

    Adjuvant therapy for high-risk patients [12] :

    • Imatinib has also been approved for adjuvant therapy in patients with GISTs
    • Imatinib 400 mg PO daily for 3 years following complete gross resection of CD117-positive GIST has shown an improvement in overall survival and recurrence-free survival compared with a treatment duration of 1 year [13, 14]
    • Extending adjuvant imatinib to 5 years has been shown to continue preventing (or delaying) recurrences, but nearly half of those treated discontinued the imatinib early due to toxicity. [15, 16]
    • Adjuvant imatinib will be less effective and is therefore not recommended in cases of a PDGFRA D842V mutation or an SDH-deficient or NF-related GIST. [9, 10, 11]

    Persistent or metastatic disease

    The primary treatment for metastatic GISTs is imatinib. Surgery may be indicated in patients who have locally advanced or previously unresectable disease after a positive response to preoperative imatinib, or with limited disease progression on systemic therapy. [1]  

    Recommended therapy:

    • Imatinib 400 mg PO daily [17, 18, 19, 20] : For patients with a known KIT exon 9 mutation, dose can be escalated to 800 mg (400 mg PO BID) [8]
    • Progression of disease on imatinib 400 mg PO daily: May escalate dose to 800 mg (400 mg PO BID daily) as tolerated
    • In patients with a known PDGFRA D842V mutation conferring imatinib resistance, sunitinib is a reasonable option. Some data indicate that dasatinib or olaratumab may have some activity in this population, as well. [21, 22]
    • In patients with an SDH-deficient or NF-related GIST, imatinib is not recommended because of resistance. [10, 11]  In this situation, sunitinib or regorafenib would be options. [23, 24]
    • Sunitinib 50 mg PO daily for 4 wk, then 2 wk off (4/2 schedule); efficacy and better tolerance have been reported with off-label continuous dosing at 37.5 mg PO daily [25, 26]
    • Regorafenib: 160 mg PO daily for the first 21 days of each 28-day cycle; indicated for locally advanced, unresectable GISTs that no longer respond to imatinib or sunitinib [24]

    Progressive disease

    See the list below:

    • Options are limited for patients with progressive disease whose GISTs are resistant to both imatinib, sunitinib, and regorafinib.
    • Other options include the use of sorafenib, dasatinib, or nilotinib for patients who do not receive clinical benefits from imatinib and sunitinib
    • Patients continuing to progress should be recommended to enroll in clinical trials
    • Some studies recommend rechallenging patients with imatinib and sunitinib if all other options have failed
    Media Gallery
    of 0

    Find Us On

    Group 2 34A8E98B-62ED-4216-98D6-E986304F4C2E

    About

    About Medscape Privacy Policy Terms of Use Advertising Policy Help Center

    Membership

    Become a Member Email Newsletters Manage My Account

    Apps

    Medscape MedPulse News CME & Education

    WebMD Network

    WebMD MedicineNet eMedicineHealth RxList WebMD Corporate

    Editions

    English Deutsch Español Français Português
    All material on this website is protected by copyright, Copyright © 1994-2018 by WebMD LLC. This website also contains material copyrighted by 3rd parties.